#Spain #Myotonic Dystrophy #RNA Therapeutics #Valencia #ARTHEx Biotech

ARTHEx Biotech's Latest Advancement in Treating Myotonic Dystrophy Type 1

In a significant step forward for the treatment of Myotonic Dystrophy Type 1 (DM1), ARTHEx Biotech has released preclinical findings showing that their investigational therapy, ATX-01, may reverse behavioral alterations associated with this debilitating disorder. As a clinical-stage biotechnology firm, ARTHEx focuses on RNA-based therapies aimed at neuromuscular conditions, and this new data marks a pivotal moment in DM1 research.

The study, titled "Fatty-acid–based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in Myotonic Dystrophy Type 1," has been formally published in Cell Reports Medicine. This groundbreaking work provides the first scientific evidence linking molecular corrections in the brain to observable behavioral improvements in animal models suffering from DM1 — a major milestone in understanding and treating this genetic condition.

DM1 is a complex illness that not only affects muscle function but also significantly impacts cognitive abilities and behavioral patterns. People afflicted with this condition often face a decreased quality of life due to these multisystemic effects. Traditional treatments have struggled to effectively address the neurological components of DM1, often failing to penetrate the central nervous system (CNS).

Dr. Beatriz Llamusí, Co-founder and Chief Scientific Officer of ARTHEx Biotech, emphasized the importance of these findings, stating, "This research represents a major step forward for the DM1 field. For the first time, we are seeing a clear connection between improvement of molecular alterations in the brain and meaningful functional improvements in a DM1 model. Importantly, this was achieved through systemic delivery using our BOOST-ON™ platform, which has the potential to simplify treatment while addressing the full spectrum of the disorder."

Key Findings from the Research

The study revealed impressive results demonstrating the ability of the lipid-conjugated antimiR-23b to effectively reach the brain after intravenous administration. The findings included:

• - Crossing the Blood-Brain Barrier: The systemic delivery showcased a capability to target the CNS directly, a vital aspect considering the limitations of many past therapeutic options.
• - Engagement of Disease Mechanisms: The therapy was able to increase the protein levels of MBNL1/2, critical for preventing RNA mis-splicing and reducing toxic DMPK transcripts that exacerbate DM1.
• - Correction of Disease Biology: Significant improvements were observed in brain regions affected by the disorder, including beneficial alterations in splicing abnormalities.
• - Functional Behavioral Improvement: Animals treated with ATX-01 showed normalization in behavioral activities that had been disrupted by the disease, such as exploratory measures.
• - Safety Profile: Notably, the treatment demonstrated a favorable tolerability profile, with no significant adverse effects observed.

These findings suggest that ATX-01 could serve as a disease-modifying approach, simultaneously addressing both muscular and neurological symptoms prevalent in DM1.

Dr. Frédéric Legros, Executive Chairman and CEO, stated, "This publication further strengthens our conviction in the ArthemiR program. While our clinical efforts have been centered on the muscular manifestations of DM1, these new preclinical results highlight the potential for central nervous system involvement — an area of significant unmet need."

Future Directions for ARTHEx Biotech

The company is advancing ATX-01 through the Phase I/IIa ArthemiR trial and is committed to collaborating with regulatory bodies, investigators, and advocacy groups to expedite progress toward a viable treatment option. Their BOOST-ON™ platform is critical in this endeavor, combining selective RNA oligonucleotides with optimized delivery strategies to effectively penetrate target tissues, including the muscle, heart, and brain — areas crucial in understanding and treating the multifaceted impacts of DM1.

As ARTHEx Biotech progresses with their efforts in this innovative realm, the implications for future treatments of DM1 patients could be significant, potentially reshaping the therapeutic landscape for a condition historically identified with limited options and significant challenges.

For more detailed information, interested parties can visit the company's clinical trials page or follow the ongoing updates on their therapeutic advancements through their official website.